샘플 요청 목록

 카트 문의
시장보고서
상품코드
1796044

세계의 트루리시티 시장

Trulicity
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 471 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

트루리시티 세계 시장은 2030년까지 59억 달러에 달할 전망

2024년에 49억 달러로 추정되는 트루리시티 세계 시장은 2024-2030년 분석 기간 동안 CAGR 3.3%로 성장하여 2030년에는 59억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 2형 당뇨병 적응증은 CAGR 2.4%를 기록하며 분석 기간 종료시에는 31억 달러에 달할 것으로 예측됩니다. 비만 치료제 부문은 분석 기간 동안에 CAGR 4.5%의 성장이 전망됩니다.

미국 시장은 13억 달러로 추정, 중국은 CAGR 6.0%로 성장 예측

미국의 트루리시티 시장은 2024년에 13억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 12억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 6.0%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.4%와 2.4%로 예측됩니다. 유럽에서는 독일이 CAGR 1.8%로 성장할 것으로 예측됩니다.

트루리시티(둘라글루타이드) 세계 시장 - 주요 동향과 촉진요인 정리

트루리시티의 임상적 역할은 무엇인가?

트루리시티(듀라글루티드)는 주 1회 투여하는 글루카곤 유사 펩타이드-1 수용체 작용제(GLP-1 RA)로 제2형 당뇨병의 혈당 조절 개선을 위해 승인된 약물입니다. 인슐린 분비 촉진, 글루카곤 분비 억제, 위 배출 지연, 포만감 촉진으로 체중 감소를 촉진하면서 A1C를 강력하게 낮춥니다. 장시간 지속형 제형과 자동주사기 투여로 매일 투여하는 GLP-1 치료제 대비 복약 순응도와 예측가능성을 향상시킵니다.

트루리시티는 어떤 혁신으로 그 영역을 넓혀가고 있는가?

최신 용량 표시에는 A1C 제어를 개선하기 위해 더 높은 정량 단위가 포함되어 있습니다. 일회용 자동 주사기는 바늘이 숨겨져 있고, 장치의 피드백이 단순화되어 있어 환자가 쉽게 사용할 수 있습니다. 심혈관계 결과 연구(REWIND) 데이터는 당뇨병 성인에서 주요 심혈관계 이상반응(MACE)을 유의미하게 감소시켜 심장 및 대사 위험 관리에 대한 처방을 강화하는 것으로 나타났습니다. 가치 기반 치료와 원격의료의 실제 통합은 치료 시작과 순응도 모니터링을 더욱 간소화할 수 있습니다.

트루리티 대상자

일차 진료 의사, 당뇨병 교육 의사, 내분비 전문의는 혈당과 체중의 이중 효과를 필요로 하는 T2DM 진단을 받은 환자에게 자주 처방합니다. 순환기내과 의사들은 ASCVD 위험이 있는 당뇨병 환자에게 트루리시티를 처방하는 경우가 늘고 있습니다. 약사 주도의 만성 치료 클리닉에서는 프로토콜에 따라 점진적으로 증가시키는 데 사용됩니다. 원격의료 프로그램에서는 지방이나 의료 혜택이 부족한 지역에서도 교육 및 원격 추적 관찰이 용이하기 때문에 트루리티가 채택되고 있습니다.

트루리시티의 채택을 촉진하는 요인은 무엇일까?

트루리시티 시장 성장의 원동력은 제2형 당뇨병 유병률 증가, 강력한 심장 및 신장 결과 데이터, 주 1회 투여의 편의성에 대한 선호도, CV 혜택이 있는 GLP-1을 선호하는 지불자의 폭넓은 급여 적용 등입니다. 또한, A1C와 체중을 감소시키는 실제 임상에서의 유효성이 시장에서의 입지를 강화하고 있습니다. 새로운 처방전 자부담 프로그램 및 제조업체 지원 서비스를 통해 접근성이 향상됩니다. 치료 초기에 GLP-1을 권장하는 가이드라인이 늘어나는 가운데, 트루리시티는 전문의와 일차의료진 모두에게 선호되는 선택이 되고 있습니다.

부문

적응증(2형 당뇨병, 비만, 심혈관질환), 제형(주사제, 펜형 디바이스, 프리필드 시린지), 유통 채널(소매 약국, 병원 약국, 온라인 유통 채널), 최종사용자(병원 최종사용자, 재택의료 최종사용자, 기타 최종사용자)

조사 대상 기업 사례

  • Amgen
  • AstraZeneca
  • Boehringer Ingelheim
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Innovent Biologics
  • Jiangsu Hansoh Pharma Group
  • Merck & Co.
  • Novartis
  • Novo Nordisk
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Roche/Genentech
  • Sanofi
  • Sun Pharmaceutical Industries
  • Takeda Pharmaceutical
  • Valo Therapeutics
  • Zealand Pharma

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계별 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.09.02

Global Trulicity Market to Reach US$5.9 Billion by 2030

The global market for Trulicity estimated at US$4.9 Billion in the year 2024, is expected to reach US$5.9 Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Type 2 Diabetes Indication, one of the segments analyzed in the report, is expected to record a 2.4% CAGR and reach US$3.1 Billion by the end of the analysis period. Growth in the Obesity Indication segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 6.0% CAGR

The Trulicity market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 6.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Trulicity (Dulaglutide) Market - Key Trends & Drivers Summarized

What Clinical Role Does Trulicity Play?

Trulicity (dulaglutide) is a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved to improve glycemic control in type 2 diabetes. By amplifying insulin secretion, suppressing glucagon, slowing gastric emptying, and promoting satiety, it enables robust A1C reduction while promoting weight loss. Its long-acting formulation and autoinjector delivery increase adherence and predictability compared to daily GLP-1 therapies.

What Innovations Are Expanding Trulicity’s Reach?

Latest dose presentations include higher-quantitative units for improved A1C control. Its single-dose autoinjector features hidden needle and simplified device feedback that ease patient use. Cardiovascular outcome trial data (REWIND) show significant reduction in major adverse cardiovascular events (MACE) in diabetic adults-pushing prescribing into cardio-metabolic risk management. Real-world integration into value-based care and telehealth further streamlines therapy initiation and adherence monitoring.

Who Is Trulicity Serving?

Primary-care physicians, diabetes educators, and endocrinologists frequently prescribe it to newly diagnosed T2DM patients needing dual glycemic and weight benefits. Clinical cardiologists are increasingly prescribing Trulicity for diabetic patients with ASCVD risks. Within pharmacist-led chronic care clinics, it's used for protocolized titration. Telemedicine programs serving rural or medically underserved communities adopt it due to ease of training and remote follow-up.

What’s Driving the Adoption of Trulicity?

The growth in the Trulicity market is driven by increasing type 2 diabetes prevalence, strong cardio-renal outcome data, preference for weekly dosing convenience, and broader reimbursement from payers prioritizing GLP-1s with CV benefit. Its real-world effectiveness in reducing A1C and body weight together strengthens market position. Novel prescription copay programs and manufacturer support services improve access. As guidelines increasingly recommend GLP-1s early in treatment, Trulicity remains a preferred option in both specialist and primary-care environments.

SCOPE OF STUDY:

The report analyzes the Trulicity market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Type 2 Diabetes Indication, Obesity Indication, Cardiovascular Disease Indication); Form (Injection Form, Pen Device Form, Pre-Filled Syringe Form); Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Distribution Channel); End-Use (Hospitals End-Use, Homecare Settings End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Amgen
  • AstraZeneca
  • Boehringer Ingelheim
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Innovent Biologics
  • Jiangsu Hansoh Pharma Group
  • Merck & Co.
  • Novartis
  • Novo Nordisk
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Roche / Genentech
  • Sanofi
  • Sun Pharmaceutical Industries
  • Takeda Pharmaceutical
  • Valo Therapeutics
  • Zealand Pharma

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Trulicity - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Type 2 Diabetes Throws the Spotlight on Trulicity as a Leading GLP-1 Therapy
    • Clinical Efficacy in Glycemic Control and Cardiovascular Risk Reduction Drives Physician Preference
    • Increased Adoption of Weekly Injectable Therapies Improves Patient Adherence and Quality of Life
    • Expansion of GLP-1 Receptor Agonist Class in Treatment Guidelines Supports Market Continuity for Trulicity
    • Positive Outcomes in Real-World Evidence and Long-Term Studies Reinforce Trust Among Healthcare Providers
    • Wider Insurance Coverage and Reimbursement in Developed Markets Boost Prescription Volumes
    • Growth in Obesity-Linked Comorbidities Creates Opportunities for Dual Indication Positioning
    • Improved Pen Injector Technology Enhances Ease of Use and Minimizes Injection Discomfort
    • Rising Demand for Non-Insulin Options in Early Treatment Stages Sustains Market Momentum
    • Global Expansion by the Manufacturer and Marketing Partnerships Strengthen Brand Penetration
    • Emergence of GLP-1-Based Combination Therapies Positions Trulicity as a Foundational Treatment Component
    • Healthcare Provider Education and Direct-to-Consumer Marketing Improve Awareness and Treatment Initiation
    • Competitive Pressure from New Entrants Spurs Continuous Innovation and Lifecycle Management
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Trulicity Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Trulicity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Trulicity by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Trulicity by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Type 2 Diabetes Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Type 2 Diabetes Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Type 2 Diabetes Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Obesity Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Obesity Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Obesity Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Cardiovascular Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Cardiovascular Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Cardiovascular Disease Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Homecare Settings End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Homecare Settings End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Homecare Settings End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Injection Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Injection Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Injection Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Pen Device Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Pen Device Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Pen Device Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Pre-Filled Syringe Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Pre-Filled Syringe Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Pre-Filled Syringe Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Trulicity Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: USA 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Canada 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Canada 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • Trulicity Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Japan 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Japan 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Japan 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • Trulicity Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 77: China Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: China 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 80: China Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: China 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 83: China Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: China 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: China 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • Trulicity Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Trulicity by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Trulicity by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Europe 16-Year Perspective for Trulicity by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Europe 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Europe 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Europe 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Europe 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • Trulicity Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 104: France Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: France Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: France 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 107: France Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: France Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: France 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 110: France Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: France 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 113: France Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: France 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • Trulicity Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 116: Germany Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Germany 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 119: Germany Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Germany Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Germany 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Germany 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Germany 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 128: Italy Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Italy 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 131: Italy Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Italy Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Italy 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Italy 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 137: Italy Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Italy Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Italy 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Trulicity Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 140: UK Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: UK Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: UK 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 143: UK Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: UK Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: UK 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 146: UK Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: UK 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 149: UK Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: UK Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: UK 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 152: Spain Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Spain Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Spain 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 155: Spain Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Spain Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Spain 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 158: Spain Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Spain Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Spain 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 161: Spain Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Spain Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Spain 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 164: Russia Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Russia Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Russia 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 167: Russia Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Russia Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Russia 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 170: Russia Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Russia Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Russia 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 173: Russia Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Russia Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Russia 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Europe Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Rest of Europe 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Europe Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Rest of Europe 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Europe Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Rest of Europe 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Europe Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Europe 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Trulicity Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Trulicity by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 189: Asia-Pacific Historic Review for Trulicity by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Asia-Pacific 16-Year Perspective for Trulicity by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Asia-Pacific Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Asia-Pacific 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Asia-Pacific Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Asia-Pacific 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Asia-Pacific Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Asia-Pacific 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Asia-Pacific Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Asia-Pacific 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Trulicity Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 203: Australia Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Australia Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Australia 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 206: Australia Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Australia Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Australia 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 209: Australia Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Australia Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Australia 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 212: Australia Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Australia Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Australia 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • INDIA
    • Trulicity Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 215: India Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: India Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: India 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 218: India Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: India Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: India 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 221: India Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: India Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: India 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 224: India Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: India Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: India 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 227: South Korea Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: South Korea Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: South Korea 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 230: South Korea Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: South Korea Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: South Korea 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 233: South Korea Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: South Korea Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: South Korea 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 236: South Korea Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: South Korea Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: South Korea 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Asia-Pacific Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: Rest of Asia-Pacific 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Asia-Pacific Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: Rest of Asia-Pacific 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Asia-Pacific Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: Rest of Asia-Pacific 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Asia-Pacific Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: Rest of Asia-Pacific 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Trulicity Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 251: Latin America Recent Past, Current & Future Analysis for Trulicity by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 252: Latin America Historic Review for Trulicity by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: Latin America 16-Year Perspective for Trulicity by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 254: Latin America Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Latin America Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: Latin America 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 257: Latin America Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Latin America Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Latin America 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 260: Latin America Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Latin America Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Latin America 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 263: Latin America Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Latin America Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Latin America 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 266: Argentina Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Argentina Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Argentina 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 269: Argentina Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Argentina Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Argentina 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 272: Argentina Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Argentina Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Argentina 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 275: Argentina Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Argentina Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Argentina 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 278: Brazil Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Brazil Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: Brazil 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 281: Brazil Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Brazil Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: Brazil 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 284: Brazil Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Brazil Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: Brazil 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 287: Brazil Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Brazil Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: Brazil 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 290: Mexico Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Mexico Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: Mexico 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 293: Mexico Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Mexico Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: Mexico 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 296: Mexico Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Mexico Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Mexico 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 299: Mexico Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Mexico Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Mexico 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Latin America Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: Rest of Latin America 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Latin America Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 307: Rest of Latin America 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Latin America Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 310: Rest of Latin America 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Rest of Latin America Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 313: Rest of Latin America 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Trulicity Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 314: Middle East Recent Past, Current & Future Analysis for Trulicity by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 315: Middle East Historic Review for Trulicity by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 316: Middle East 16-Year Perspective for Trulicity by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 317: Middle East Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Middle East Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 319: Middle East 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 320: Middle East Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Middle East Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 322: Middle East 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 323: Middle East Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Middle East Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 325: Middle East 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 326: Middle East Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Middle East Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 328: Middle East 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 329: Iran Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Iran Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 331: Iran 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 332: Iran Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Iran Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 334: Iran 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 335: Iran Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Iran Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 337: Iran 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 338: Iran Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Iran Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 340: Iran 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 341: Israel Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Israel Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 343: Israel 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 344: Israel Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Israel Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 346: Israel 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 347: Israel Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Israel Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 349: Israel 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 350: Israel Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Israel Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 352: Israel 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Saudi Arabia Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 355: Saudi Arabia 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Saudi Arabia Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 358: Saudi Arabia 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Saudi Arabia Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 361: Saudi Arabia 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Saudi Arabia Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 364: Saudi Arabia 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 365: UAE Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: UAE Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 367: UAE 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 368: UAE Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: UAE Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 370: UAE 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 371: UAE Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: UAE Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 373: UAE 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 374: UAE Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 375: UAE Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 376: UAE 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Rest of Middle East Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 379: Rest of Middle East 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Rest of Middle East Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 382: Rest of Middle East 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Rest of Middle East Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 385: Rest of Middle East 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Rest of Middle East Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 388: Rest of Middle East 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AFRICA
    • Trulicity Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 389: Africa Recent Past, Current & Future Analysis for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Africa Historic Review for Trulicity by Indication - Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 391: Africa 16-Year Perspective for Trulicity by Indication - Percentage Breakdown of Value Sales for Type 2 Diabetes Indication, Obesity Indication and Cardiovascular Disease Indication for the Years 2014, 2025 & 2030
    • TABLE 392: Africa Recent Past, Current & Future Analysis for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Africa Historic Review for Trulicity by End-Use - Hospitals End-Use, Homecare Settings End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 394: Africa 16-Year Perspective for Trulicity by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Homecare Settings End-Use and Other End-Uses for the Years 2014, 2025 & 2030
    • TABLE 395: Africa Recent Past, Current & Future Analysis for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Africa Historic Review for Trulicity by Form - Injection Form, Pen Device Form and Pre-Filled Syringe Form Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 397: Africa 16-Year Perspective for Trulicity by Form - Percentage Breakdown of Value Sales for Injection Form, Pen Device Form and Pre-Filled Syringe Form for the Years 2014, 2025 & 2030
    • TABLE 398: Africa Recent Past, Current & Future Analysis for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Africa Historic Review for Trulicity by Distribution Channel - Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 400: Africa 16-Year Perspective for Trulicity by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies, Hospital Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제